Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: Data from a 6-month controlled study followed by a 12-month open-label extension study

Journal of Neurology

Volumn 259, Issue 2, 2012, Pages 284-291

  Meier, Thomas ^a   Perlman, Susan L ^b   Rummey, Christian ^a   Coppard, Nicholas J ^a   Lynch, David R ^c  

^a Santhera Pharmaceuticals   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Ataxia; Idebenone; International Cooperative Ataxia Rating Scale; Movement disorder

Indexed keywords

CATENA; IDEBENONE; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FRIEDREICH ATAXIA; FRIEDREICH ATAXIA RATING SCALE; HUMAN; INTERNATIONAL COOPERATIVE ATAXIA RATING SCALE; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; SPEECH; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ANTIOXIDANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FRIEDREICH ATAXIA; HUMANS; MALE; TREATMENT OUTCOME; UBIQUINONE;

EID: 84856732716     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6174-y     Document Type: Article

References (22)

1. T Klockgether R Lüdtke B Kramer, et al. 1998 The natural history of degenerative ataxia: a retrospective study in 446 patients Brain 121 589 600 9577387 10.1093/brain/121.4.589
2. A Durr M Cossee Y Agid, et al. 1996 Clinical and genetic abnormalities in patients with Friedreich's ataxia N Engl J Med 335 1169 1175 8815938 10.1056/NEJM199610173351601 1:STN:280:DyaK28zpvFShsQ%3D%3D
3. JB Schulz S Boesch K Bürk, et al. 2009 Diagnosis and treatment of Friedreich ataxia: a European perspective Nat Rev Neurol 5 222 234 19347027 10.1038/nrneurol.2009.26
4. AE Harding 1981 Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and interfamilial clustering of clinical features Brain 104 589 620 7272714 10.1093/brain/104.3. 589 1:STN:280:DyaL38%2FgtFeqsg%3D%3D
5. Tsou AY, Paulsen EK, Lagedrost SJ et al (2011) Mortality in Friedreich ataxia. J Neurol Sci (in press)
6. R Santos S Lefevre D Sliwa, et al. 2010 Friedreich ataxia: molecular mechanism, redox considerations, and therapeutic opportunities Antiox Redox Signal 13 651 690 10.1089/ars.2009.3015 1:CAS:528:DC%2BC3cXosFaksbo%3D
7. C Tonon R Lodi 2008 Idebenone in Friedreich's ataxia Expert Opin Pharmacother 9 2327 2337 18710357 10.1517/14656566.9.13.2327 1:CAS:528:DC%2BD1cXpvFygu7s%3D
8. JB Schulz NA Di Prospero K Fischbeck 2009 Clinical experience with high dose idebenone in Friedreich ataxia J Neurol 256 Suppl 1 42 45 19283350 10.1007/s00415-009-1008-x 1:CAS:528:DC%2BD1MXht1antrbI
9. NA Di Prospero A Baker N Jeffries, et al. 2007 Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomized, placebo-controlled trial Lancet Neurol 6 10 878 886 17826341 10.1016/S1474-4422(07)70220-X 1:CAS:528:DC%2BD2sXht1Krtr7F
10. R Artuch A Aracil A Mas, et al. 2002 Friedreich's ataxia: idebenone treatment in early stage patients Neuropediatrics 33 4 190 193 12368988 10.1055/s-2002-34494 1:CAS:528:DC%2BD38XotlGisLs%3D
11. P Arnold O Boulat R Maire, et al. 2006 Expanding view of phenotype and oxidative stress in Friedreich's ataxia patients with and without idebenone Schweizer Archiv für Neurology und Psychiatrie 157 169 176
12. M Pineda J Arpa R Montero, et al. 2008 Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up Eur J Paediatr Neurol 12 6 470 475 18234531 10.1016/j.ejpn.2007.11.006
13. DR Lynch SL Perlman T Meier 2010 A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich Ataxia Arch Neurol 67 8 941 947 20697044 10.1001/archneurol.2010.168
14. P Trouillas T Takayanagi M Hallett, et al. 1997 International cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome J Neurol Sci 145 205 211 9094050 10.1016/S0022-510X(96)00231-6 1:STN:280:DyaK2s3ksl2htQ%3D%3D
15. SH Subramony W May D Lynch, et al. 2005 Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale Neurology 64 1261 1262 15824358 10.1212/01.WNL.0000156802.15466.79 1:STN:280:DC%2BD2M7ptFertw%3D%3D
16. J Folker B Murdoch L Cahill, et al. 2010 Dysarthria in Friedreich's ataxia: a perceptual analysis Folia Phoniatr Logop 62 97 103 20424464 10.1159/000287207
17. A Singh E Epstein LM Myers, et al. 2010 Clinical measures of dysarthria in Friedreich ataxia Mov Disord 25 108 121 20014117
18. MC Fahey L Corben V Collins, et al. 2007 How is disease progress in Friedreich's ataxia best measured? A study of four rating scales J Neurol Neurosurg Psychiatry 78 411 413 17056635 10.1136/jnnp.2006.096008 1:STN:280:DC%2BD2s7msFegug%3D%3D
19. P Ribai F Pousset ML Tanguy, et al. 2007 Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up Arch Neurol 64 558 564 17420319 10.1001/archneur.64.4.558
20. DA Sival ER Brunt 2009 The international cooperative Ataxia Rating Scale shows strong age-dependency in children Dev Med Child Neurol 51 571 572 19459907 10.1111/j.1469-8749.2009.03334.x
21. LS Friedman JM Farmer S Perlman, et al. 2010 Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design Mov Disord 25 426 432 20063431 10.1002/mds.22912
22. NA Di Prospero CJ Sumner SR Penzak, et al. 2007 Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia Arch Neurol 64 803 808 17562928 10.1001/archneur.64.6.803